Seasonal influenza vaccination in Europe – Vaccination recommendations and coverage rates for 2013-14 and 2014-15
Overview of vaccination recommendations and coverage rates in the EU Member States for the 2013–14 and 2014–15 influenza seasons.
Two evaluations of the response to the 2009 Pandemic in Spain: Surveillance and Vaccines and antiviralsArchived
Two official evaluations have been made by the national Ministry of Health of Spain of their country’s response to the 2009 influenza pandemic. The reviews focused on two particular topics - Surveillance and Vaccines and Antivirals.
Recommendations on antivirals in European countries are appropriate, but remain underutilised in practice
Current recommendations in EU countries to use neuraminidase inhibitors (antivirals) for patients with severe influenza are supported by the available evidence, concludes a new expert opinion report from ECDC which is now open for public consultation.
Factsheet about seasonal influenza
Influenza is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and sometimes the lungs. It can cause mild to severe illness, and at times can lead to death. The best way to prevent flu is by getting a flu vaccine each year.
Infographic: How do antivirals treat and protect against influenza?
This ECDC infographic explains how antivirals treat and protect against influenza. The recommendations to treat patients with severe influenza are based on the evidence from randomised controlled trials, observational studies, extrapolation from studies, and a generally benign safety profile of these medicines.
Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza
This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States. Recommendations to treat patients with severe influenza – or those at high risk of the complications of influenza – and provide prophylaxis to the most vulnerable and their families are based on the evidence from randomised controlled trials, evidence from observational studies, extrapolation from studies, and a generally benign safety profile of these medicines.
Seasonal influenza vaccination and antiviral use in EU/EEA Member States
Overview of vaccine recommendations for 2017–2018 and vaccination coverage rates for 2015–2016 and 2016–2017 influenza seasons.
Influenza vaccination coverage rates insufficient across EU Member States
None of the European Union (EU) Member States could demonstrate that they reach the EU target of 75% influenza vaccination coverage for vulnerable groups, according to a new report from the European Centre for Disease Prevention and Control (ECDC).